Derisking Drug-Induced Carcinogenicity for Novel Therapeutics

Area of Science:

• Drug development
• Molecular carcinogenesis
• Toxicology

Background:

• Assessing carcinogenic potential of innovative drugs is challenging.
• Novel modalities like cell and gene therapies require distinct cancer hazard identification.
• Current methods may not adequately address unique risks of new therapeutic modalities.

Purpose of the Study:

• To emphasize the need for customized weight-of-evidence cancer risk assessments.
• To balance preclinical hazard identification with clinical product labeling and risk management.
• To review advances in molecular carcinogenesis for enhanced interpretation of cancer risk.

Main Methods:

• Review of advances in molecular carcinogenesis.
• Assessment of preclinical indicators of neoplasia.
• Systematic evaluation of drug targets for tumorigenic phenotypes using genetic models and cancer genome resources.

Main Results:

• Novel therapeutic modalities necessitate distinct approaches for cancer hazard identification.
• Advances in molecular carcinogenesis can improve mechanistic interpretation and preclinical indicators.
• Drug targets should be systematically assessed for oncogenic potential.

Conclusions:

• Customized weight-of-evidence cancer risk assessments are crucial for innovative drugs.
• Balancing preclinical data with clinical risk management is essential.
• Integrating molecular carcinogenesis insights and genetic assessments enhances drug safety evaluation.